Wageningen University

Self-Amplifying mRNA Vaccines Face Slow Adoption Despite Promise

7 months ago

• Self-amplifying mRNA (samRNA) vaccines offer potential advantages like extended efficacy and lower doses compared to traditional mRNA vaccines. • Regulatory hurdles and a lack of extensive experience have slowed the widespread adoption of samRNA technology. • Arcturus Therapeutics' Kostaive, approved in Japan, remains one of the few samRNA vaccines to reach the market, benefiting from pandemic-era acceleration. • Technical complexities and concerns about potential immune responses to the replicon component pose challenges for samRNA vaccine development.